The global artificial insemination market size was US$ 1,921.2 million in 2021. The global artificial insemination market is forecast to grow to USD 3,177.9 million by 2030 by registering a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2022 to 2030.

Artificial insemination is the medical process performed for people suffering from infertility who want to have children. In this process, semen is introduced into the female reproductive tract through other artificial means. This process is majorly recommended to couples undergoing unexplained infertility problems associated with normal sperm production, abnormal seminal fluid, etc.

Factors Influencing the Market

Favorable government initiatives, focused on improving healthcare infrastructure, will propel the artificial insemination market forward. For instance, nearly 14 states in the United States have included infertility treatment in their medical insurance plans. Thus, such initiatives will drive the artificial insemination market forward.
Constantly growing cases of infertility will upsurge the demand for the artificial insemination market during the study period. According to a study by World Health Organization (WHO), nearly 10% of women suffer from infertility. Furthermore, the rising prevalence of erectile dysfunction and Polycystic Ovary Syndrome (PCOS) will also contribute to the growth of the artificial insemination market during the forecast period.
Steadily rising changes in lifestyle and the growth rate of working women preferring conceiving at a later age may increase the chances of complications. Thus, it will boost the growth of the artificial insemination market. In addition, growing alcohol consumption, changing lifestyle, and reducing sperm count may result in infertility in men. Thus, it will positively affect the artificial insemination market during the forecast period.
The risk associated with artificial insemination may limit the growth of the market during the study period.
COVID-19 Impact Analysis

The COVID-19 pandemic brought various challenges along. The entire healthcare industry witnessed substantial disruptions, which affected the global artificial insemination market. As the rate of COVID-19 infection raised abruptly, it drew the focus of the entire sector to the COVID-19 patients. Hospitals stopped allowing other operations in order to control this deadly situation. Thus, the market for artificial insemination witnessed various obstacles during the pandemic period.

Regional Analysis

Based on the regions, the Asia-Pacific artificial insemination market is projected to hold the highest market share during the forecast period. It is due to the growing infertility rate in this region. Furthermore, rising awareness about effective treatment options for infertility will bring ample growth opportunities along. In addition, changing lifestyles and rising spending on healthcare will also contribute to the growth of the artificial insemination market during the forecast period.

Competitors in the Market

Genea Limited
Rinovum Womens Health, LLC
Vitrolife
FUJIFILM Irvine Scientific
Pride Angel
KITAZATO CORPORATION
Rocket Medical plc.
Other Prominent Players
Market Segmentation

The global artificial insemination market segmentation focuses on Type, Source, End-User, and Region.

By Type Outlook

Intrauterine Insemination
Intracervical Insemination
Intravaginal Insemination
Intratubal Insemination
By Source Type Outlook

AIH-Husband
AID-Donor
By End-Use Outlook

Fertility Clinics & Others
Home
By Regional Outlook

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America